ONWARD Medical to Advance Parkinson’s Disease Pipeline with Support from The Michael J. Fox Foundation and US Department of DefenseThe Michael J. Fox Foundation for Parkinson’s Research is supporting a study addressing mobility challenges in Parkinson’s disease; the first participant was enrolled in late 2024
ONWARD Medical's ARC-EX System Now Available on US Veterans Affairs Online Procurement PlatformsONWARD ARC-EX System for spinal cord injury is now available for purchase through VA Federal Supply Schedule and GSA Advantage platforms
ONWARD Medical Announces First Commercial Sales of ARC-EX SystemUW Medicine and Next Steps Chicago both purchased systems in late December 2024
ONWARD Medical Provides Q3 2024 Update and Year-to-Date HighlightsRaised EUR 50 million in new capital with cornerstone investment from Ottobock, now the Company’s top investor
ONWARD Medical Awarded Grant to Study Potential for ARC-BCI Therapy to Restore Movement after StrokeGrant supports the first clinical trials studying the potential for brain-computer interface (BCI) and artificial intelligence (AI) technology to restore thought-driven movement after stroke
ONWARD Medical Schedules Webcast to Provide Q3 2024 Update and Year-to-Date HighlightsCompany to provide update on significant milestones and near-term plans, including its recent successful financing and agreements with Ottobock and CEA
ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024EINDHOVEN, the Netherlands, Oct. 31, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its investigational ARC-EX System has been named one of TIME's Best Inventions of 2024.
ONWARD® Medical Publishes Closing of Bookbuild OfferingTHIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD® Medical Publishes Prospectus for Listing of New SharesTHIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD® Medical Signs Agreement with CEA for Exclusive Rights to Clinatec’s WIMAGINE® Brain-Computer Interface (BCI) TechnologyTHIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD® Medical Reports Half Year 2024 Results and Provides a Business UpdateTHIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD® Medical and Partners Awarded Christopher & Dana Reeve Foundation Grant to Further Study Brain-Computer Interface SystemGrant will enable ONWARD Medical, CEA-Clinatec and .NeuroRestore to evaluate the use of the ONWARD ARC-BCI™ System to restore thought-driven movement of the hands and arms after spinal cord injury (SCI)
ONWARD® Medical Reaffirms 2024 Strategic Priorities and Releases Unaudited Q2 Financial HighlightsCompany expects to commercialize the investigational ARC-EX® System in Q4 2024 and has commenced launch preparations
ONWARD® Medical Publishes Annual Sustainability SummaryCompany strengthens sustainability practices prior to commercialization
ONWARD® Medical Announces Publication Highlighting Evidence-based Programming for ARC-EX® TherapyFramework to determine stimulation parameters for ONWARD ARC-EX Therapy are published in the journal Neuromodulation: Technology at the Neural Interface
ONWARD® Medical Obtains Debt Financing with up to €52.5 Million Secured Loan from Runway Growth Capital LLCTHIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD® Medical Announces Participation in Stifel European Healthcare SummitCEO Dave Marver will meet with investors to discuss the Company’s achievements and upcoming milestones
ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe ConferenceCEO Dave Marver and trial participant Gert-Jan Oskam will discuss ONWARD ARC-BCI™ Therapy during main stage presentation
ONWARD® Medical Announces Results of Annual General Meeting of ShareholdersTHIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD® Medical Schedules Webcast to Provide Q1 2024 Business UpdateEINDHOVEN, the Netherlands, May 15, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will host a webcast to discuss its Q1 2024 business highlights.
ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed ResolutionsEINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today has convened the 2024 Annual General Meeting of Shareholders (AGM), which will include consideration of the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on June 13, 2024.
ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update WebcastEINDHOVEN, the Netherlands, April 11, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will publish Full Year 2023 Financial Results and host a webcast to discuss business highlights.
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy rating and Target Price of EUR 12.00 per share. This is a premium of 140% to the closing price of EUR 5.00 on April 8, 2024.
ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® SystemFDA clearance would allow the Company to market its breakthrough therapy to improve or restore hand and arm function after spinal cord injury in the US
ONWARD® Medical Publishes Closing of Accelerated Bookbuild Offering and Public Offering in FranceNOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
ONWARD® Medical Publishes Prospectus for Listing of New SharesNOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of an Accelerated Bookbuild Offering and by Way of a Public Offering in FranceNOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize OptionEINDHOVEN, the Netherlands, March 20, 2024 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
ONWARD® Medical Successfully Completes Benchmark Testing on Path to Commercialize ARC-EX® SystemThird-party tests from leading US lab confirm printed circuit board assembly (PCBA) conforms to prevailing international electrical standards, a requirement for commercial launch
ONWARD® Medical Reaffirms Guidance, Shares 2024 Strategic Priorities, and Releases Unaudited Q4 Financial HighlightsTHIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD® Medical Accepted to New US FDA TAP Program for Development of its ARC-BCI™ SystemThe Company is one of the first brain-computer interface entrants accepted into this program, intended to optimize the commercialization pathway for breakthrough medical technology
KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per ShareEINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that KBC Securities, part of the KBC Group -- a leading Belgian integrated bank-insurance group -- has initiated research coverage of ONWARD Medical with a Buy rating and Target Price of EUR 10.00 per share. This is a premium of 161% to the closing price of EUR 3.83 on February 8, 2024.
ONWARD® MEDICAL ANNOUNCES PRESENTATION AT BIOCAPITAL EUROPECEO Dave Marver will present on the Company’s use of brain-computer interface technology and progress toward planned commercialization of ARC-EX® later this year
ONWARD® ARC Therapy™ Highlighted at 2024 Annual Meeting of the North American Neuromodulation Society (NANS)Clinical experience with investigational ARC-EX® Therapy showcased on the main stage and in clinical abstracts during the 2024 NANS Annual Meeting
ONWARD® to Participate in Basel Healthtech Conference 2024CEO Dave Marver will discuss the Company’s leadership in health technology, including spinal cord stimulation with brain-computer interfaces
ONWARD® to Participate in Degroof Petercam Healthcare ConferenceCEO Dave Marver will provide update on the Company’s progress toward launch of its first therapy later this year
ONWARD® Announces Start of HemON NL Clinical StudyHemON NL is evaluating the use of ARC-IM® Therapy to address hemodynamic instability after spinal cord injury
ONWARD® Reports Q3 Business Update and Year-To-Date HighlightsEINDHOVEN, the Netherlands, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Completing activities required for ARC-EX® FDA submission
ONWARD Schedules Webcast to Provide Third Quarter 2023 Business UpdateEindhoven, Netherlands, Oct. 11, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury, today announced that it will host a webcast to discuss its Q3 2023 business highlights.
